Posted on 9/20/19
Regenxbio And RGX-501 In Homozygous Familial Hypercholesterolemia
Summary Liver Therapy Forum weekly digest provides an overview of what's happening in therapeutics for dyslipidemia in 2019. The focus this week is Regenxbio Inc. As . . .
Posted on 9/20/19
Regenxbio And RGX-501 In Homozygous Familial Hypercholesterolemia
SummaryLiver Therapy Forum weekly digest provides an overview of what's happening in therapeutics for dyslipidemia in 2019. The focus this week is Regenxbio Inc.As a leader . . .
Posted on 5/30/19
Pfizer And PF-05221304 In NASH: The Lead Clinical Asset
Summary One of Pfizer’s scientific forte is the clinical development of effective therapeutics for dyslipidemia, cardiovascular, and metabolic disorders. PF-05221304, the lead investigative drug candidate, is . . .
Posted on 5/30/19
Pfizer And PF-05221304 In NASH: The Lead Clinical Asset
SummaryOne of Pfizer’s scientific forte is the clinical development of effective therapeutics for dyslipidemia, cardiovascular, and metabolic disorders.PF-05221304, the lead investigative drug candidate, is an acetyl-CoA . . .
Posted on 2/19/19
Pfizer In NASH: Left Behind And The Desperate Refocus
Summary Pfizer is a proven pioneer of therapeutics for HIV infection, autoimmune, cardiovascular and gastrointestinal diseases, as well as hematological and oncological ailments. At the end . . .
Posted on 2/19/19
Pfizer In NASH: Left Behind And The Desperate Refocus
SummaryPfizer is a proven pioneer of therapeutics for HIV infection, autoimmune, cardiovascular and gastrointestinal diseases, as well as hematological and oncological ailments.At the end of Q4 . . .
Posted on 9/20/18
Pfizer And Conatus: Emricasan And NASH
SummaryPfizer has proven itself to be a pioneer of therapeutics for HIV infection, autoimmune, cardiovascular and gastrointestinal diseases as well as hematological and oncological ailments.Pfizer had . . .
Posted on 6/25/18
Immune Pharmaceuticals And Bertilimumab: A Work In Progress
Investment Analysis:Immune Pharmaceuticals (NASDAQ:IMNP) is a clinical stage biopharmaceutical company focused on the development and commercialization of its lead candidate Bertilimumab, for the treatment of Bullous . . .
Philadelphia
